AOD-9604 + CJC Blend
Also known as: AOD-9604 + CJC Blend, Fat Loss GH Stack
A combination pairing the fat-loss GH fragment AOD-9604 with the GHRH analog CJC-1295, studied to layer direct lipolytic activity onto elevated endogenous growth hormone.
Last updated
Mechanism of Action
This blend combines AOD-9604, the lipolytic C-terminal fragment of GH that stimulates fat breakdown via beta-3 adrenergic signaling without raising IGF-1, with CJC-1295, a GHRH-receptor agonist that increases endogenous GH and IGF-1. The rationale is to pair a targeted fat-mobilizing peptide with an overall increase in GH-driven metabolism. The two address fat loss through partly overlapping but distinct routes.
- Half-life
- Combined: AOD-9604 ~30 min; CJC-1295 no-DAC ~30 min or DAC ~days
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Combines direct lipolysis (AOD-9604) with elevated GH (CJC-1295)
- Aims to enhance fat metabolism
- AOD component does not raise IGF-1 directly
- May support body recomposition in research
- Convenient combined preparation
Potential Side Effects
- Water retention and tingling (from CJC-1295 component)
- Injection-site irritation
- Headache or flushing
- Limited evidence for additive fat-loss efficacy
Common Dosing
Research protocols reference combining the individual ranges, e.g., ~250-500 mcg AOD-9604 with ~100 mcg CJC-1295 daily. Educational reference only.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy (GH/IGF-1 elevation)
- Uncontrolled diabetes
- Pregnancy or breastfeeding
- Not approved for human use
AOD-9604
A modified fragment of the C-terminus of human growth hormone (residues 176-191) studied for fat-loss effects without the broader growth-promoting actions of full GH.
CJC-1295
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
Tesamorelin
A stabilized GHRH analog FDA-approved to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Studied for its strong effect on visceral adipose tissue.
Ipamorelin
A selective ghrelin receptor agonist (growth hormone secretagogue) prized for stimulating GH release with minimal effect on cortisol or prolactin. Considered one of the gentler GH peptides.
- View
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
2001
- View
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
2001
- View
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006
- View
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
2026